Skip to content

Ansa Biotechnologies Appoints Jason T. Gammack as CEO

  • Published

Gammack is joining the company as it completes its early access program and prepares for a full commercial launch of its rapid enzymatic synthesis for complex clonal genes and gene fragments. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.

View the press release.